155 related articles for article (PubMed ID: 20730610)
1. Adjuvant activity of GP96 C-terminal domain towards Her2/neu DNA vaccine is fusion direction-dependent.
Pakravan N; Hashemi SM; Hassan ZM
Cell Stress Chaperones; 2011 Jan; 16(1):41-8. PubMed ID: 20730610
[TBL] [Abstract][Full Text] [Related]
2. Comparison of adjuvant activity of N- and C-terminal domain of gp96 in a Her2-positive breast cancer model.
Pakravan N; Hassan ZM
Cell Stress Chaperones; 2011 Jul; 16(4):449-57. PubMed ID: 21359667
[TBL] [Abstract][Full Text] [Related]
3. N-terminally fusion of Her2/neu to HSP70 decreases efficiency of Her2/neu DNA vaccine.
Pakravan N; Soudi S; Hassan ZM
Cell Stress Chaperones; 2010 Sep; 15(5):631-8. PubMed ID: 20224916
[TBL] [Abstract][Full Text] [Related]
4. Targeting of the non-mutated tumor antigen HER2/neu to mature dendritic cells induces an integrated immune response that protects against breast cancer in mice.
Wang B; Zaidi N; He LZ; Zhang L; Kuroiwa JM; Keler T; Steinman RM
Breast Cancer Res; 2012 Mar; 14(2):R39. PubMed ID: 22397502
[TBL] [Abstract][Full Text] [Related]
5. GP96 C-terminal improves Her2/neu DNA vaccine.
Pakravan N; Soleimanjahi H; Hassan ZM
J Gene Med; 2010 Apr; 12(4):345-53. PubMed ID: 20232284
[TBL] [Abstract][Full Text] [Related]
6. Efficient induction of a Her2-specific anti-tumor response by dendritic cells pulsed with a Hsp70L1-Her2(341-456) fusion protein.
Fu Q; Wu Y; Yan F; Wang N; Wang W; Cao X; Wang Y; Wan T
Cell Mol Immunol; 2011 Sep; 8(5):424-32. PubMed ID: 21785448
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic HER2/Neu DNA vaccine inhibits mouse tumor naturally overexpressing endogenous neu.
Lin CC; Chou CW; Shiau AL; Tu CF; Ko TM; Chen YL; Yang BC; Tao MH; Lai MD
Mol Ther; 2004 Aug; 10(2):290-301. PubMed ID: 15294176
[TBL] [Abstract][Full Text] [Related]
8. Fusion to Listeriolysin O and delivery by Listeria monocytogenes enhances the immunogenicity of HER-2/neu and reveals subdominant epitopes in the FVB/N mouse.
Singh R; Dominiecki ME; Jaffee EM; Paterson Y
J Immunol; 2005 Sep; 175(6):3663-73. PubMed ID: 16148111
[TBL] [Abstract][Full Text] [Related]
9. Enhanced efficacy of DNA vaccination against Her-2/neu tumor antigen by genetic adjuvants.
Chang SY; Lee KC; Ko SY; Ko HJ; Kang CY
Int J Cancer; 2004 Aug; 111(1):86-95. PubMed ID: 15185348
[TBL] [Abstract][Full Text] [Related]
10. Anti-HER2/neu IgG3-(IL-2) and anti-HER2/neu IgG3-(GM-CSF) promote HER2/neu processing and presentation by dendritic cells: implications in immunotherapy and vaccination strategies.
Dela Cruz JS; Trinh KR; Chen HW; Ribas A; Morrison SL; Penichet ML
Mol Immunol; 2006 Feb; 43(6):667-76. PubMed ID: 15908002
[TBL] [Abstract][Full Text] [Related]
11. Enhancement of HCV polytope DNA vaccine efficacy by fusion to an N-terminal fragment of heat shock protein gp96.
Pishraft-Sabet L; Kosinska AD; Rafati S; Bolhassani A; Taheri T; Memarnejadian A; Alavian SM; Roggendorf M; Samimi-Rad K
Arch Virol; 2015 Jan; 160(1):141-52. PubMed ID: 25348271
[TBL] [Abstract][Full Text] [Related]
12. Insights into the mechanism of anti-tumor immunity in mice vaccinated with the human HER2/neu extracellular domain plus anti-HER2/neu IgG3-(IL-2) or anti-HER2/neu IgG3-(GM-CSF) fusion protein.
Dela Cruz JS; Morrison SL; Penichet ML
Vaccine; 2005 Sep; 23(39):4793-803. PubMed ID: 15967544
[TBL] [Abstract][Full Text] [Related]
13. Co-administration of GP96 and Her2/neu DNA vaccine in a Her2 breast cancer model.
Pakravan N; Langroudi L; Hajimoradi M; Hassan ZM
Cell Stress Chaperones; 2010 Nov; 15(6):977-84. PubMed ID: 20544406
[TBL] [Abstract][Full Text] [Related]
14. CCL19 as an adjuvant for intradermal gene gun immunization in a Her2/neu mouse tumor model: improved vaccine efficacy and a role for B cells as APC.
Nguyen-Hoai T; Hohn O; Vu MD; Baldenhofer G; Sayed Ahmed MS; Dörken B; Norley S; Lipp M; Pezzutto A; Westermann J
Cancer Gene Ther; 2012 Dec; 19(12):880-7. PubMed ID: 23099886
[TBL] [Abstract][Full Text] [Related]
15. Immunization with a HSP65-HER2 fusion peptide selectively eliminates HER2(+) B16 melanoma cells in a xenograft tumor mouse model.
Wang J; Wang X; Chen Y; Wan M; Xiang Z; Wu X; Wei H; Wang L; Zhang P; Wang L; Yu Y
Tumour Biol; 2013 Feb; 34(1):193-201. PubMed ID: 23055194
[TBL] [Abstract][Full Text] [Related]
16. Targeted delivery of tumor antigens to activated dendritic cells via CD11c molecules induces potent antitumor immunity in mice.
Wei H; Wang S; Zhang D; Hou S; Qian W; Li B; Guo H; Kou G; He J; Wang H; Guo Y
Clin Cancer Res; 2009 Jul; 15(14):4612-21. PubMed ID: 19584156
[TBL] [Abstract][Full Text] [Related]
17. HSP110-HER2/neu chaperone complex vaccine induces protective immunity against spontaneous mammary tumors in HER-2/neu transgenic mice.
Manjili MH; Wang XY; Chen X; Martin T; Repasky EA; Henderson R; Subjeck JR
J Immunol; 2003 Oct; 171(8):4054-61. PubMed ID: 14530326
[TBL] [Abstract][Full Text] [Related]
18. Vaccination with novel combinations of anti-HER2/neu cytokines fusion proteins and soluble protein antigen elicits a protective immune response against HER2/neu expressing tumors.
Helguera G; Dela Cruz JS; Lowe C; Ng PP; Trinh R; Morrison SL; Penichet ML
Vaccine; 2006 Jan; 24(3):304-16. PubMed ID: 16125282
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of vaccination with plasmid DNA encoding for HER2/neu or HER2/neu-eGFP fusion protein against prostate cancer in rats.
Bhattachary R; Bukkapatnam R; Prawoko I; Soto J; Morgan M; Salup RR
Int Immunopharmacol; 2002 May; 2(6):783-96. PubMed ID: 12095169
[TBL] [Abstract][Full Text] [Related]
20. Enhancing the potency of HBV DNA vaccines using fusion genes of HBV-specific antigens and the N-terminal fragment of gp96.
Yan J; Liu X; Wang Y; Jiang X; Liu H; Wang M; Zhu X; Wu M; Tien P
J Gene Med; 2007 Feb; 9(2):107-21. PubMed ID: 17256801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
